# Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

> **NCT01709149** · PHASE2 · COMPLETED · sponsor: **Cytokinetics** · enrollment: 711 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** CK-2017357
- **OTHER:** Placebo tablets
- **DRUG:** Riluzole

## Key facts

- **NCT ID:** NCT01709149
- **Lead sponsor:** Cytokinetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 711 (ACTUAL)
- **Last updated:** 2020-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01709149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01709149, "Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01709149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*